Halozyme Therapeutics, Inc. announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO. Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up.

He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company. During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.

The company's executive search for a permanent Chief Financial Officer is well underway and progressing. Halozyme has engaged a leading executive search firm to identify candidates who bring the combination of capital markets expertise and strategy. Mr. Ramsay will remain in the role until a permanent CFO is appointed.

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania. Mr. Ramsay (age 61) has served as a member of the Board of Directors of Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Since 2017, he has also served on the board of directors of Exuma Biotech, Inc., a privately held biotechnology company.

Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications, from February 2018 until its acquisition by Allergan plc in October 2018. Mr. Ramsay previously served as the Company?s Chief Financial Officer from 2003 to 2009 and from 2013 until 2015. He also served as the Company?s Vice President, Corporate Development from 2009 to 2013.

Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license.